Understanding and Addressing Misinformation Among Populations That Experience Health Disparities Technical Assistance Webinar Friday, May 6, 2022 3:00-4:00 p.m. ET NIMHD will host a pre-application technical assistance webinar for prospective applicants who plan to submit applications to RFA-MD-22-008, Understanding and Addressing Misinformation Among Populations That Experience Health Disparities (R01 Clinical Trials Optional). NIH program and review staff will provide an overview of the RFA—including objectives, application instructions, and review criteria—and will be available to answer questions. Understanding and Addressing Misinformation Among Populations That Experience Health Disparities (R01 Clinical Trials Optional) Prevalent in a variety of health contexts, the COVID-19 pandemic is a leading example of how the spread of misinformation and disinformation can hamper the effectiveness of population-level efforts to address public health emergencies. Other examples include HIV/AIDS, STIs, vaccines, genetic testing, cancer, and tobacco use and cessation, among others. This initiative calls for multidisciplinary and multilevel research (see Research Framework) with a health disparities lens that recognizes the role of psychosocial and cultural factors, structural racism, distrust, and marginalization of communities. In addition, the influence of resilience or factors that impact the uptake of accurate health information is of interest. Outcomes of interest include physical and mental health, health decision-making, behavior change, adherence to evidence-based prevention and treatment guidelines/recommendations, and morbidity and mortality. This initiative targets misinformation and disinformation as public health threats and supports research to: - Understand the underlying mechanisms, and
- Test interventions to mitigate the impact of related misinformation and disinformation on health disparities and the populations that experience health disparities.
Ultimately, this research will inform public health practice. NIH Guide Number: RFA-MD-22-008 Letter of Intent Due: April 30, 2022 Open (Earliest Submission Date): May 1, 2022 |
No comments:
Post a Comment